AKTX

Akari Therapeutics
AKTX

Overview Fund Activity

14 hedge funds and large institutions have $37M invested in Akari Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 4 closing their positions.

Holders
14
Holders Change
-4
Holders Change %
-22.22%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Wells Fargo
1
Wells Fargo
California
$7K

Top Sellers

1
FCMI
1
Foresite Capital Management III
California
$0
2
RCM
2
RA Capital Management
Massachusetts
$0
3
BC
3
Boxer Capital
California
$1.05M
4
QF
4
QVT Financial
New York
$1.89M
5
UBS Group
5
UBS Group
Switzerland
$50K
Name Market Value Shares Shares
Change 		Shares
Change %
DM
1
Deerfield Management
New York
$12.7M 1,150,700 – –
VC
2
Vivo Capital
California
$5.84M 527,842 – –
BBA
3
Baker Bros. Advisors
New York
$5.5M 496,901 – –
NMC
4
NEA Management Company
Maryland
$5.01M 452,167 – –
VMI
5
VHCP Management II
New York
$4.09M 369,490 – –
QF
6
QVT Financial
New York
$1.89M 209,121 -49,000 -19%
BC
7
Boxer Capital
California
$1.05M 95,011 -44,888 -32%
GTC
8
Ghost Tree Capital
New York
$516K 46,622 – –
Deutsche Bank
9
Deutsche Bank
Germany
$258K 23,387 – –
UBS Group
10
UBS Group
Switzerland
$50K 4,537 -17,165 -79%
Wells Fargo
11
Wells Fargo
California
$7K 625 +625 New
Morgan Stanley
12
Morgan Stanley
New York
$3K 229 – –
FCMI
13
Foresite Capital Management III
California
– – -197,072 Closed
RCM
14
RA Capital Management
Massachusetts
– – -101,439 Closed
SM
15
Sabby Management
Florida
– – -17,428 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– – -600 Closed
Citigroup
17
Citigroup
New York
$0 30 – –
AG
18
Advisor Group
Arizona
$0 25 – –